Cancer Epigenetics Program (03)

癌症表观遗传学计划 (03)

基本信息

批准号：
10427548
负责人：
Johnathan R. Whetstine
金额：
$ 0.71万
依托单位：
RESEARCH INST OF FOX CHASE CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-07-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10427548
关键词：
Abbreviations Address Antineoplastic Agents Applied Research Basic Science Bioinformatics Biological Biological Markers Biological Specimen Banks Biology Biometry Blood Cells Cancer Biology Cancer Center Support Grant Cancer Control Cancer Etiology Cancer Intervention Cell Culture Techniques Cell Separation Clinic Clinical Clinical Research Clinical Trials Collaborations Colon Carcinoma Complex Comprehensive Cancer Center DNA DNA Methylation Detection Development Diagnosis Direct Costs Disease Drug Targeting EZH2 gene Enhancers Environment Epigenetic Process Faculty Fostering Fox Chase Cancer Center Foxes Funding Gene Expression Genetic Transcription Genomics Goals Health system Hematologic Neoplasms Histopathology Facility Interleukin-6 Intervention Investigation Knowledge Laboratory Animals Malignant Neoplasms Malignant neoplasm of urinary bladder Mediating Mission Molecular Molecular Target Morbidity - disease rate Mutation Normal Cell Outcome Participant Patients Pattern Peer Review Pharmaceutical Preparations Population Study Prognosis Proteins Publications Reader Regulation Reporting Research Research Personnel Resource Sharing Risk Assessment Role Scientist Solid Neoplasm Structure System Testing Therapeutic Therapeutic Intervention Tissues Training Transgenic Mouse Facility Translating Translational Research Universities University Hospitals Untranslated RNA Validation Work animal facility cancer biomarkers cancer cell cancer prevention cancer risk cancer therapy career clinically relevant demethylation design early detection biomarkers epigenetic regulation epigenetic therapy epigenome epigenomics high throughput screening histone modification imaging facilities improved improved outcome interest leukemia malignant breast neoplasm medical schools member molecular modeling mortality multidisciplinary next generation novel novel strategies outcome prediction preclinical study preventive intervention programs recruit response specific biomarkers standard of care targeted treatment translational clinical trial

项目摘要

PROJECT SUMMARY/ABSTRACT – CANCER EPIGENETICS PROGRAM The Cancer Epigenetics (CE) Program, led by Issa and Studitsky is a new Program at Fox Chase Cancer Center (FCCC). The CE Program is designed to integrate basic and applied research in the field of epigenetics. It is comprised of 19 Primary Members. Program funding is $5M (project direct costs) annually, including $2.4M in peer-reviewed funding of which $1M is from the NCI. CE members have been highly productive since Program initiation in 2012, generating 232 publications, with 9% representing intra- programmatic and 27% representing inter-programmatic collaborations. The CE Program takes advantage of the breadth and depth of faculty expertise in cancer epigenetics arising from the 2012 affiliation between FCCC and Temple University, to advance the overall goal of improving cancer outcomes through new approaches in detection, prognosis and therapy. The CE Program has four overarching themes: 1) Epigenomics: To decipher normal and cancer epigenomes, with the translational goal of discovering biomarkers of cancer risk, prognosis and response to therapy; 2) Readers, Writers and Erasers: To study the proteins that establish, read, modulate and perpetuate epigenetic marks, with the translational goal of discovering potential targets of therapy; 3) Development and Disease: To study epigenetics in normal and abnormal development and relate this information to what is known about cancer epigenetics and biology. The translational goal of this theme is in understanding cancer etiology, and discovering ways to reprogram the epigenome for therapeutic purposes; 4) Epigenetic Therapy: To develop epigenetically-targeted therapeutic approaches and test them in pre-clinical and clinical studies. These themes are developed by investigators working in multidisciplinary teams to identify and address the complex factors that contribute to cancer risk, cancer development and cancer treatment. This new Program was made possible by the recruitment of multiple faculty members at all career stages (junior and senior) and with diverse interests (basic to clinical), and has resulted in a strongly integrated program with both R01 funded basic research and rapidly accruing investigator-initiated clinical trials. These collaborative efforts have created a productive research environment that fosters the identification of new biomarkers of cancer risk, novel molecular targets for preventive intervention, and the successful development and implementation of novel approaches to cancer therapy. CE Program members have successfully accrued 394 research participants into interventional and non-interventional studies during the last funding cycle, and have benefited from the use of 11 of the 12 CCSG-supported Shared Resources at FCCC.

项目摘要/摘要——癌症表观遗传学计划由 Issa 和 Studitsky 领导的癌症表观遗传学 (CE) 项目是 Fox Chase Cancer 的一个新项目 CE 计划旨在整合领域的基础研究和应用研究。表观遗传学由 19 名主要成员组成，每年计划资金为 500 万美元（项目直接成本）。包括 240 万美元的同行评审资金，其中 100 万美元来自 NCI 成员。自 2012 年计划启动以来富有成效，产生了 232 份出版物，其中 9% 代表内部程序化合作，27% 代表程序间合作。 CE 项目利用了癌症表观遗传学领域教师专业知识的广度和深度自 2012 年 FCCC 与天普大学的合作以来，旨在推进改善的总体目标通过新的检测、预后和治疗方法取得癌症结果。 CE 计划有四个总体主题：1) 表观基因组学：破译正常和癌症表观基因组，其转化目标是发现癌症风险、预后和治疗反应的生物标志物；读者、作家和橡皮擦：研究建立、阅读、调节和延续表观遗传的蛋白质标记，其转化目标是发现潜在的治疗靶点；3) 发育和疾病：研究正常和异常发育中的表观遗传学，并将这些信息与已知的信息联系起来癌症表观遗传学和生物学该主题的转化目标是了解癌症病因学，以及发现用于治疗目的的表观基因组重编程方法；4) 表观遗传疗法：开发表观遗传学靶向治疗方法并在临床前和临床研究中对其进行测试。由多学科团队的研究人员开发，用于识别和解决复杂因素制定了这项新计划，以促进癌症风险、癌症发展和癌症治疗。通过在所有职业阶段（初级和高级）招聘多名具有不同背景的教员来实现这一目标兴趣（基础到临床），并导致了一个与 R01 资助的基础项目紧密结合的项目研究和迅速积累的研究者发起的临床试验创造了一个。富有成效的研究环境，促进癌症风险新生物标志物的识别，新颖预防性干预的分子目标，以及新型药物的成功开发和实施 CE 计划成员已成功招募 394 名研究参与者。上一个资助周期中的干预性和非干预性研究，并受益于使用 FCCC 12 个 CCSG 支持的共享资源中的 11 个。